FDA review extended for ruxolitinib cream, while Incyte benefits from potential Trump-era tariffs, leading to analyst upgrades and recommendations.
6 reports, 2 independent
Updated Sep 20
Gone quiet
- Reports
- 6
- Developments
- 2
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA review extended for ruxolitinib cream, while Incyte benefits from potential Trump-era tariffs, leading to analyst upgrades and recommendations.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Incyte and ST commercialize ruxolitinib cream in Australia via a partnership.1 source
Incyte benefits from Trump-era tariffs; UBS raises price target, Cohen recommends stock.1 source
Keep exploring
The entities involved
- FDA
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
-
Incyte
American pharmaceutical company
Related events
Coverage
Newest first; wire copies grouped- prnewswire.com
- Insider MonkeyIncyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects Incyte Corporation (NASDAQ:INCY) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On